Ratner Jennifer C, Wilson Janet, Roberts Kevin, Armitage Catherine, Barton Richard Christopher
Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Genitourinary Medicine, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
Sex Transm Infect. 2025 Jan 29;101(1):21-26. doi: 10.1136/sextrans-2024-056186.
Azoles have been the mainstay of recurrent vulvovaginal candidiasis (RVVC) for many years. Because of a recent anecdotal increase in non- yeasts (NCAY) and azole-resistant cases, their prevalence was calculated from cultures for yeasts in women with complicated/RVVC over 3 years.
Retrospective data search of vaginal cultures from adult women in Leeds, UK between April 2018 and March 2021 was conducted. Samples with clinical details of complicated/RVVC had full yeast identification and antifungal susceptibility performed. Differences in prevalence between 12-month periods were determined using χ tests.
Over the 3 years, cultures were performed on 5461 vaginal samples from women with clinical information indicating they had complicated/RVVC, RVVC, with 1828 (33.5%) growing yeasts.Over 85% of yeasts each year were , however the proportion declined yearly with an increase in NCAY species. was the most frequent NCAY species isolated, increasing from 2.8% in 2018-19 to 6.8% in 2020-21. Total NCAY species increased from 6.0% in 2018-19 to 12.6% in 2020-21. Fluconazole-sensitive dose-dependant (SDD) and resistant isolates increased from 3.5% in 2018-19 to 7.7% in 2019-20 and 9.6% in 2020-21. Most resistance was in and the majority of cases were seen in primary care. Most fluconazole non-sensitive isolates were either SDD or resistant to itraconazole (77% and 23%, respectively) and were intermediate or resistant to voriconazole (36.4% and 60%, respectively).
There was a significant increase in the prevalence of NCAY and fluconazole-resistant in complicated/RVVC cultures over these 3 years. Successful treatment of such cases can be very challenging. The exact reasons for this increase remain unclear but it follows a policy change that encouraged a clinical diagnosis and empirical treatment of vulvovaginal candidiasis, rather than fungal culture, in primary care.
多年来,唑类药物一直是复发性外阴阴道念珠菌病(RVVC)的主要治疗药物。由于近期非酵母菌(NCAY)和对唑类耐药病例的传闻有所增加,我们计算了3年中患有复杂性/RVVC的女性酵母菌培养物中它们的患病率。
对2018年4月至2021年3月期间英国利兹成年女性的阴道培养物进行回顾性数据检索。对具有复杂性/RVVC临床细节的样本进行了完整的酵母菌鉴定和抗真菌药敏试验。使用χ检验确定12个月期间患病率的差异。
在这3年中,对5461份来自有临床信息表明患有复杂性/RVVC、RVVC的女性的阴道样本进行了培养,其中1828份(33.5%)培养出酵母菌。然而,每年超过85%的酵母菌为白色念珠菌,但其比例逐年下降,NCAY菌种有所增加。光滑念珠菌是分离出的最常见的NCAY菌种,从2018 - 2019年的2.8%增至2020 - 2021年的6.8%。NCAY菌种总数从2018 - 2019年的6.0%增至2020 - 2021年的12.6%。对氟康唑敏感的剂量依赖性(SDD)和耐药菌株从2018 - 2019年的3.5%增至2019 - 2020年的7.7%以及2020 - 2021年的9.6%。大多数耐药情况发生在光滑念珠菌,且大多数病例出现在初级保健机构。大多数对氟康唑不敏感的分离株要么对SDD耐药,要么对伊曲康唑耐药(分别为77%和23%),并且对伏立康唑呈中度或耐药(分别为36.4%和60%)。
在这3年中,复杂性/RVVC培养物中NCAY和对氟康唑耐药的光滑念珠菌患病率显著增加。成功治疗此类病例可能极具挑战性。这种增加的确切原因尚不清楚,但这是由于一项政策变化导致的,该政策鼓励在初级保健中对外阴阴道念珠菌病进行临床诊断和经验性治疗,而非真菌培养。